Leadership

Engimmune was co-founded in 2021 by Dr. Rodrigo Vazquez-Lombardi, Prof. Sai Reddy and Dr. Søren Mouritsen (formerly CEO) based on inventions by Dr. Vazquez-Lombardi, who serves as the company CSO, and Prof. Reddy, who serves as Chairman of the Scientific Advisory Board (SAB). 
 
Dr. Lars Nieba, a leading pharma and biotech executive with decades of experience in leadership roles across preclinical, clinical and commercial development of biotherapeutics , serves as the company CEO. Prof. Bent Jakobsen, a pioneer in TCR-based therapies (co-founder and former CSO of Adaptimmune and Immunocore) serves as Chairman of Engimmune’s Board of Directors. 
​
Engimmune closed its seed financing round in May 2022, which was co-led by Pureos Bioventures and Novo Holdings, bringing decades of drug development experience to its Board with the appointment of Dr. Dominik Escher (Pureos) and Dr. Jørgen Søberg Petersen (Novo) as directors. 

​

In June 2023, Engimmune appointed Dr. Annalisa D'Andrea as non-executive director, a highly experienced immunologist and biotech executive, further strengthening its positioning toward commercial and clinical development of TCR therapeutics.